Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust Sells 4,163 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 4,163 shares of the firm’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $37.13, for a total value of $154,572.19. Following the sale, the chief executive officer now owns 509,986 shares in the company, valued at approximately $18,935,780.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock opened at $43.13 on Wednesday. Twist Bioscience Co. has a 52-week low of $11.81 and a 52-week high of $44.92. The company’s 50 day moving average price is $34.15 and its 200-day moving average price is $31.52. The stock has a market capitalization of $2.51 billion, a price-to-earnings ratio of -12.84 and a beta of 1.64.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.05. The business had revenue of $75.30 million for the quarter, compared to analyst estimates of $70.70 million. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The company’s revenue was up 25.1% on a year-over-year basis. During the same quarter last year, the firm earned ($1.06) EPS. As a group, equities research analysts forecast that Twist Bioscience Co. will post -3.17 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on TWST. Robert W. Baird increased their price objective on Twist Bioscience from $39.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. The Goldman Sachs Group raised shares of Twist Bioscience from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $25.00 to $45.00 in a research note on Wednesday, January 17th. Barclays upped their price objective on shares of Twist Bioscience from $40.00 to $45.00 and gave the company an “overweight” rating in a research note on Friday, May 3rd. Evercore ISI lifted their target price on shares of Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Finally, Scotiabank upped their price target on shares of Twist Bioscience from $43.00 to $48.00 and gave the company a “sector outperform” rating in a research report on Monday. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Twist Bioscience presently has a consensus rating of “Buy” and an average price target of $42.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. EdgeRock Capital LLC bought a new stake in shares of Twist Bioscience in the 4th quarter worth approximately $30,000. Federated Hermes Inc. bought a new stake in Twist Bioscience in the third quarter valued at $29,000. China Universal Asset Management Co. Ltd. increased its position in Twist Bioscience by 96.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,470 shares of the company’s stock valued at $30,000 after purchasing an additional 721 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in Twist Bioscience by 51.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,453 shares of the company’s stock worth $70,000 after purchasing an additional 1,179 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new stake in shares of Twist Bioscience in the 1st quarter worth about $124,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.